Cadrenal Therapeutics(CVKD) - 2025 Q4 - Annual Report

Drug Development and Clinical Trials - The company is advancing CAD-1005, a first-in-class selective 12-LOX inhibitor for treating heparin-induced thrombocytopenia (HIT), with a Phase 3 pivotal trial planned following a successful End-of-Phase 2 meeting with the FDA on March 26, 2026[24][40]. - CAD-1005 has received orphan drug designation (ODD) and Fast Track designation from the FDA for the treatment and prevention of HIT, indicating its potential significance in addressing this life-threatening condition[32][41]. - The Phase 1 clinical studies of CAD-1005 demonstrated good tolerability with no serious adverse events reported among 96 healthy subjects[38]. - A Phase 2 pilot study of CAD-1005 showed a high rate of thrombotic events (>75%) in the placebo group compared to 50% in the CAD-1005 group, although it did not meet its primary endpoint of platelet count recovery[39]. - The company plans to secure sufficient financing to commence the pivotal Phase 3 clinical trial for CAD-1005, which is crucial for its development[29][40]. - The company is focused on addressing the underlying pathophysiology of HIT, which existing therapies do not adequately target, potentially positioning CAD-1005 as a transformative treatment[34][36]. - The company is currently focused on the development of CAD-1005, having shifted from its previous focus on tecarfarin[165]. - The company has not yet received the final minutes from its EOP2 meeting with the FDA, which may contain additional comments affecting the Phase 3 trial protocol[176]. - The Phase 2 trial of CAD-1005 in patients with HIT enrolled only 24 patients out of a planned 60 and was terminated early, indicating challenges in patient recruitment[205]. - The company faces significant clinical risks that could impede the advancement of CAD-1005 and its second-generation oral candidates[177]. Financial Position and Funding - The company had an accumulated deficit of approximately $39.0 million as of December 31, 2025, and a net loss of approximately $13.2 million for the fiscal year ended December 31, 2025[160]. - The company expects to incur significant expenses and continued losses from operations for the foreseeable future, indicating a need for additional financing to support its business strategy[160]. - The company plans to raise additional capital to fund its planned clinical trials and support development and commercialization efforts for its product candidates[171]. - The company may need to relinquish significant rights to its technologies or grant licenses on unfavorable terms if it raises funds through partnering or licensing arrangements[160]. - The company anticipates that future capital requirements will be funded through a combination of private and public equity offerings, debt financings, and strategic collaborations[173]. - The company will require additional financing prior to commencing any clinical trial and to meet anticipated cash requirements for at least the next twelve months[171]. - The company faces risks related to its financial position and need for capital, which could adversely affect its ability to continue as a going concern[160]. Regulatory Environment - The company is subject to extensive regulatory requirements, which require significant time and financial resources for compliance and approval processes[103][104]. - The FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate drug efficacy, with trials typically involving several hundred to several thousand patients[109]. - The FDA has 60 days to determine if an NDA is accepted for filing, with standard review applications typically reviewed within 10 to 12 months and priority review applications within 6 to 8 months[114]. - Orphan drug designation can provide a seven-year exclusive marketing period in the U.S. for drugs treating rare diseases affecting fewer than 200,000 individuals, along with potential grant funding of up to $500,000 per year for four years[121]. - Accelerated approval allows for early drug approval based on surrogate or intermediate clinical endpoints, significantly shortening the time required for clinical trials[124]. - The cost of preparing and submitting an NDA is substantial, with manufacturers potentially assessed up to five program fees for a fiscal year for prescription drug products identified in a single approved NDA[113]. - The FDA may impose sanctions or discontinue a clinical trial if it believes the trial is not compliant with requirements or poses unacceptable risks to patients[110]. - The company has never submitted a New Drug Application (NDA) to the FDA and relies on third-party contract research organizations (CROs) for assistance in the approval process[214]. Market Potential and Competition - The estimated peak annual market revenue potential for CAD-1005 in patients with HIT is approximately $825 million, while the combined peak annual U.S. market revenue potential for tecarfarin and frunexian is estimated at $2 billion[96][97]. - The company faces substantial competition from major pharmaceutical companies and other entities in the development and commercialization of its product candidates[91][95]. - The commercial success of product candidates will depend on obtaining favorable labeling from regulatory authorities, which may not align with the company's expectations[206]. - The commercial success of the company's product candidates will depend on market acceptance by physicians, patients, and healthcare payors, which is influenced by factors such as efficacy, safety, and pricing[211]. Manufacturing and Supply Chain - The company has completed the manufacturing of tecarfarin drug product in accordance with cGMP and has contracts with third-party CDMOs for development and supply, but lacks long-term supply agreements[87][88]. - The company does not have any long-term supply agreements or commercialization partnerships with manufacturers for its product candidates, which may expose it to risks in production and distribution[218]. - The company anticipates that if approved by the FDA, it will be able to enter into agreements with third parties for the manufacturing and distribution of its product candidates[220]. - The company faces risks related to supply disruptions, regulatory compliance, and loss of key manufacturing partners that could delay product development and commercialization[223]. Intellectual Property and Agreements - The company acquired the Veralox assets, including CAD-1005 and related compounds, on December 10, 2025, enhancing its pipeline and intellectual property portfolio[26][27]. - The company has acquired intellectual property from Veralox and eXIthera, including U.S. and foreign patents for 12-LOX inhibitors and Factor XIa inhibitors, with various expiration dates for these patents[98][100]. - The company entered into a Veralox Purchase Agreement for $200,000 in cash, with contingent milestone payments not exceeding $15 million based on clinical and regulatory achievements[75]. - The eXIthera Purchase Agreement involved acquiring assets for $50,000 in transaction costs and up to $15 million in milestone payments based on clinical and regulatory events[83][84]. - The company is obligated to pay eXIthera a 2% royalty on annual net sales of pharmaceutical products containing compounds from the eXIthera Purchase Agreement, payable from the first commercial sale until the expiration of patent claims[84]. Employee and Corporate Structure - The company has five full-time employees and approximately thirty-five consultants and contractors as of March 27, 2025[146]. - The corporate headquarters are leased with a monthly rent of $2,346, under a lease agreement that commenced on November 1, 2025[148]. - The company qualifies as an "emerging growth company," allowing it to take advantage of reduced reporting requirements until certain revenue or debt thresholds are met[152]. - The company has opted for an extended transition period to comply with new accounting standards, potentially delaying compliance compared to other public companies[153].